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Effect of phosphorus supplementation on weight gain and
waist circumference of overweight/obese adults: a randomized
clinical trial
JJ Ayoub1,4, MJA Samra1,4, SA Hlais2, MS Bassil3 and OA Obeid1
BACKGROUND: Phosphorus status is inversely correlated with body weight; however, the effect of phosphorus supplementation
on body weight in a controlled design has not been studied.
METHODS: This is a double-blind, randomized, placebo-controlled trial of 63 adults aged 18–45 years with a body mass index (BMI)
of ⩾ 25 kgm− 2 and normal kidney function at the American University of Beirut. Participants were randomly assigned to the
placebo or phosphorus group where daily placebo or phosphorus supplements were ingested with three main meals (breakfast,
lunch and dinner) for a period of 12 weeks. Primary outcomes were changes in anthropometric measures, blood metabolites
(including lipid proﬁle, glucose and insulin) and subjective appetite scores. The trial is registered with Clinical Trial.gov,
NCT02329990.
RESULTS: Body weight was signiﬁcantly lower in the phosphorus group when compared with the placebo group (−0.65 kg (95%
conﬁdence interval (CI) − 1.69 to 0.40) vs 1.13 kg (95% CI 0.19 to 2.06), P= 0.01). Similarly, BMI and waist circumference were
signiﬁcantly lower in the phosphorus group when compared with the placebo group (−0.24 kgm− 2 (95% CI − 0.59 to 0.12) vs
0.42 kgm− 2 ( 95% CI 0.05 to 0.78), P= 0.01; − 3.62 cm (95% CI− 4.90 to − 2.33) vs 0.38 cm ( 95% CI− 0.44 to 1.20), Po0.001;
respectively). Several parameters of subjective appetite scores were decreased in the phosphorus-supplemented group.
CONCLUSIONS: Phosphorus supplementation for 12 weeks signiﬁcantly decreases body weight, BMI, waist circumference and
subjective appetite scores. These ﬁndings support a promising role of the mineral phosphorus in the prevention and management
of obesity, especially abdominal adiposity. The exact mechanisms of action and longer-term effects still need to be elucidated.
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INTRODUCTION
Obesity is increasing at alarming rates in many high-, medium-
and low-income countries.1 This is contributing to the develop-
ment of many metabolic diseases, including diabetes and
cardiovascular disease.2
Modernization, including food industrialization and globaliza-
tion of food markets, has been correlated with the increased
consumption of products containing negligible amounts of
phosphorus such as reﬁned cereals (whereby reﬁnement reduces
phosphorus content by ∼ 70%), oils, sugars and sweeteners that
are currently contributing to 450% of the food supply (kcal per
capita per day) in most countries.3 This has caused a decrease in
daily phosphorus ingestion to ∼ 1–1.5 g day− 1,4,5 as compared
with our ancestors’ estimated intake of 2.5 g day− 1 (based on
primarily raw, unprocessed foods with a 2500 kcal day− 1 diet and
∼ 1mg phosphorus per kcal).3
Low phosphorus status has been positively associated with
increased body weight.3,6,7 This may be attributed to the impact of
hepatic adenosine triphosphate (ATP), which depends on
adequate dietary supply of phosphorus, on suppressing food
intake.3,8,9 This mechanism is supported by an inverse relation
between body weight and hepatic ATP status.10–12 In line with
that, we have previously found that phosphorus addition to
carbohydrate preloads signiﬁcantly reduces ad libitum energy
intake at subsequent meal.13
Given the increased prevalence of obesity among individuals
consuming abundant quantities of food containing low levels of
phosphorus, it is reasonable to postulate that decreased
phosphorus intake may be involved in the development of
obesity and its metabolic abnormalities. Hence, we conducted a
randomized, placebo-controlled trial to examine the effects of 12-
week phosphorus supplementation on body weight, body mass
index (BMI), waist circumference and subjective appetite scores in
overweight and obese adults.
MATERIALS AND METHODS
Participants
After approval of the study by the institutional review board at the
American University of Beirut (Beirut, Lebanon), 63 adults aged 18 to 45
years with a BMI ⩾ 25 kgm− 2, who provided signed informed consent,
were recruited from the general public using poster advertisements or
direct approach. Details about recruitment, randomization and follow-up
are presented in Figure 1. Exclusion criteria included glomerular ﬁltration
rate o60ml min− 1 per 1.73m2, presence of any signiﬁcant medical
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disease, pregnancy or lactation, regular administration of drugs that affect
body weight and weight change of ⩾ 3% within 3 months before the
study. The study was conducted between June 2013 and September 2014
at the American University of Beirut. We computed that the enrollment of
40 subjects (20 per group) would detect a 10% change in weight of the
placebo group, assuming the latter having a mean weight of 90 kg and s.d.
of 10 kg, with 80% power and an α of 5%. The trial is registered with
Clinical Trial.gov, NCT02329990.
Randomization and masking
This double-blind, randomized, controlled study allocated subjects into
placebo group (n= 21) or phosphorus group (n=26). Participants were
requested to take three tablets containing either 375mg phosphorus or a
placebo (Nutricap Labs, Farmingdale, NY, USA) with each main meal
(breakfast, lunch and dinner) for 12 weeks. They were asked to maintain
regular dietary and physical activity habits during the entire study course
and avoid alcohol consumption and any strenuous exercise 24 h before
their visits (at baseline, 6 weeks and 12 weeks). Assignment to intervention
or control group was made by having the principle investigator
(corresponding author) ask the eligible subjects to blindly draw an
envelope from a large box of 100 opaque, sealed envelopes (50 for each
group), each containing a 2-cm by 2-cm paper with a written code
designating intervention or control. There were no detectable differences
in size or weight between intervention and control envelopes. In addition,
both researchers and participants were blinded for the type of
supplements that were similar in size, shape, color and odor.
Procedures
Subjects were asked to attend the research unit at baseline and after 6 and
12 weeks of participation. At baseline, anthropometric measurements and
blood samples were collected and a subjective appetite questionnaire
based on Wilson et al.14 was completed. Participants were given a 6-week
supply of the allocated supplement and were asked to attend the research
unit at the end of this period. At 6 weeks, remaining tablets were collected
and counted in order to assess adherence to the allocated intervention.
Participants were then given a supply of the same type of supplementation
for the consequent 6 weeks and were asked to complete the subjective
appetite questionnaire. At 12 weeks, data were collected similar to the
baseline visit, and remaining tablets were counted to assess compliance.
Individuals who consumed 470% of the allocated tablets were excluded.
Body weight and height (without shoes) were measured to the
nearest 0.1 kg and 0.1 cm, using a calibrated Seca balance (Hamburg,
Germany) and a portable stadiometer, respectively. Blood was with-
drawn after overnight fast and samples were centrifuged for 15 min at
3500 r.p.m. at 3 °C for serum and plasma separation. Sample aliquots
were stored at − 80 °C until analysis. Serum phosphorus, creatinine,
C-reactive protein, total cholesterol, high-density lipoprotein
cholesterol, triglyceride and glucose levels were measured using the
Vitros 350 analyzer (Ortho Clinical Diagnostics, Johnson and Johnson,
Buckinghamshire, UK). The Friedwald formula15 was used to calculate
low-density lipoprotein cholesterol levels. Fasting insulin concentration
was measured using the ELISA kit (Diametra Millipore, Billerica, MA, USA).
HOMA-IR (homeostasis model assessment of insulin resistance) was
calculated as described by Matthews et al.16 Glomerular ﬁltration rate
was calculated using CKD-EPI (Chronic Kidney Disease Epidemiology
Collaboration) estimated glomerular ﬁltration rate.17
Statistical analysis
Pairwise changes from baseline to 12-week follow-up anthropometric
and biochemical variables were tested using paired t-tests, and
intergroup assessment was performed using two-sample t-test.
Repeated measures analysis of variance test was applied to analyze
intragroup variation of appetite scores at different periods of time
(baseline, 6 weeks and 12 weeks). Statistical analyses were conducted
using SPSS 22 (Chicago, IL, USA).
Role of the funding source
The study was funded by the National Council for Scientiﬁc Research,
Lebanon. The funding source had no role in the study design or conduct;
data collection, analysis, interpretation or reporting of the data; prepara-
tion, review or approval of the manuscript; or decision to submit the
manuscript for publication.
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Figure 1. Study ﬂow diagram.
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RESULTS
Subject characteristics
Baseline characteristics are shown in Table 1, and they were
similar between groups. In all, 47 participants (placebo group
n= 21; phosphorus group n= 26) completed the intervention, and
all subjects had normal glomerular ﬁltration rate (460ml min− 1
per 1.73 m2) with a mean of 114.14 (10.19) ml min− 1 per 1.73 m2
and 112.24 (13.46) ml min− 1 per 1.73 m2 for the placebo and
phosphorus groups, respectively. The mean age was 36.67 (9.76)
years in the placebo group and 34.04 (11.24) years in the
phosphorus group. No side effects were reported by participants
over the experimental period.
Anthropometric assessments
Changes in anthropometric and biochemical characteristics from
baseline to 12 weeks are shown in Table 2. Body weight of the
placebo group increased signiﬁcantly from baseline by 1.13 kg
(95% conﬁdence interval (CI) 0.19 to 2.06), whereas that of the
phosphorus group decreased by 0.65 kg (95% CI − 1.69 to 0.40).
These variations resulted in a signiﬁcant difference (P= 0.01) in the
changes in body weight between the two groups. Consequently,
the changes in BMI of the placebo group (0.42 kgm− 2, 95% CI
0.05 to 0.78) was signiﬁcantly different (P= 0.01) than that of the
phosphorus group (−0.24 kgm− 2, 95% CI − 0.59 to 0.12).
Simultaneously, waist circumference of the phosphorus group
was signiﬁcantly reduced by 3.62 cm (95% CI − 4.90 to − 2.33), and
this reduction was signiﬁcantly different (Po0.001) from the small
increase of 0.38 cm (95% CI − 0.44 to 1.20) in the waist
circumference of the placebo group.
Biochemical assessments
Placebo or phosphorus treatment for 12 weeks did not affect
serum levels of phosphorus, total cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, tri-
glyceride, glucose and C-reactive protein. Serum levels of insulin
and HOMA-IR were similar between the two treatments at
baseline and at 12 weeks, although a mild but signiﬁcant
difference was detected in their changes. This mild change is
not believed to be of clinical signiﬁcance (Table 2).
Subjective appetite scores
Baseline subjective appetite scores were similar between groups.
The changes in several parameters of subjective appetite scores
were found to decrease as the experiment progressed including
that of appetite, quantity of food to reach fullness, hunger and
number of snacks. However, changes in appetite, quantity of food
to reach fullness, taste of food and number of snacks were
signiﬁcantly reduced in the phosphorus group as compared with
the placebo as shown in Table 3.
DISCUSSION
Several dietary patterns and interventions were reported to
improve body weight.18–22 High protein diets were constantly
found to induce weight loss, probably because of their capacity to
decrease energy intake and increase energy expenditure.18,23,24
Consumption of dairy products was also shown to be inversely
related to body weight, whereby its increased intake among
overweight individuals was reported to lower body weight,19,25
irrespective of its calcium content.26 Moreover, the intake of whole
grains was shown to be negatively associated with the risk of
different components of the metabolic syndrome, including body
weight;20,21 however, the mechanism of such effect remains
uncertain.27 This raises the questions on the role of macronu-
trients in weight reduction, especially as these dietary patterns or
interventions have varied macronutrient proﬁles.22 The common
feature between these diets seems to be their phosphorus
Table 1. Baseline characteristics of the study participants
Baseline characteristics Placebo group (n=21) Phosphorus group (n= 26) Unpaired t-test, P-value
Age, mean (s.d.), years 36.67 (9.76) 34.04 (11.24) 0.396
Sex, no. (%)
Male 6 (28.57) 10 (38.46)
Female 15 (71.43) 16 (61.54)
Anthropometric measurements, mean (s.d.)
Weight, kg 92.33 (14.99) 88.33 (19.14) 0.426
Height, m 1.65 (0.08) 1.66 (0.11) 0.646
BMIa 33.73 (3.84) 31.64 (4.64) 0.099
Waist circumference, cmb 109.43 (9.90) 106.00 (12.74) 0.305
Biochemical characteristics, mean (s.d.)
Serum phosphorus, mg dl− 1 c 79.99 (41.54) 91.50 (53.20) 0.540
Total cholesterol, mg dl− 1 d 221.85 (40.66) 216.08 (42.32) 0.645
LDL-C, mg dl− 1 d 143.29 (30.47) 145.77 (33.50) 0.797
HDL-C, mg dl− 1 d 46.30 (10.98) 43.12 (11.86) 0.357
Triglycerides, mg dl− 1 d 161.50 (67.60) 137.40 (81.20) 0.284
Glucose, mg dl− 1 d 95.25 (10.56) 96.28 (11.37) 0.755
Insulin, μIU ml− 1 d 11.41 (7.77) 7.71 (7.89) 0.123
HOMA-IRd 2.81 (2.30) 1.93 (2.27) 0.210
CRP, mg l− 1 d 9.82 (5.51) 9.40 (3.93) 0.773
GFR (mlmin− 1 per 1.73m2)d 114.14 (10.19) 112.24 (13.46) 0.592
Abbreviations: BMI, body mass index; CRP, C-reactive protein; GFR, glomerular ﬁltration rate; HDL-C, high-density lipoprotein cholesterol; HOMA-IR,
homeostatic model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol. SI conversion factor: to convert serum phosphorus to
mmol l− 1, multiply by 0.323; cholesterol, LDL-C and HDL-C to mmol l− 1, multiply by 0.0259; triglycerides to mmol l− 1, multiply by 0.0113; glucose to mmol l− 1,
multiply by 0.0555. aCalculated as weight in kg divided by height in m squared. bMeasured at the midpoint between the lower rib and iliac crest. cBecause of
missing data, based on sample size of 20 and 26 for placebo and phosphorus groups, respectively. dBecause of missing data, based on sample size of 20 and
25 for placebo and phosphorus groups, respectively.
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content, as proteins, dairy products and whole grains are rich
sources of phosphorus.28 This was the rationale for our proposed
hypothesis on the involvement of low phosphorus status in the
development of obesity and metabolic syndrome.3,29
Our study found that the ingestion of 375mg phosphorus with
each main meal, over a period of 12 weeks, was able to prevent
weight gain and to reduce waist circumference among over-
weight and obese adults. However, minimal alterations were
observed in the measured biochemical parameters (lipid proﬁle,
glucose and so on) that may be attributed to the modest baseline
abnormalities in these parameters, short experimental duration
and/or to the modest anthropometric changes. The absence of
change in fasting plasma phosphorus further conﬁrms that it is
not a good marker of phosphorus intake.30
The anthropometric changes in the phosphorus group are in
line with other studies in which phosphorus status was reported
to be inversely related to body weight3,6,7,29 and waist
circumference.3,31,32 The mechanism(s) by which phosphorus
affected body weight may have been related to its involvement
in food intake control and/or energy metabolism.3 Phosphorus
availability is known to stimulate ATP production, in particular
hepatic ATP,8,33 that is believed to transmit afferent neural signals
to the central nervous system resulting in a decrease in food
intake8 through the stimulation of satiation. Such effect was
believed to be behind the impact of phosphorus addition to
different carbohydrate preloads on the suppression of ad libitum
energy intake at subsequent meal.13 In agreement, as reported in
the subjective appetite questionnaires, satiation indicated by the
quantity of food to reach fullness was reduced in the phosphorus
group; however, the number of main meals, which is an indicator
of satiety, was not reduced. Sustenance of hepatic ATP production
over the postprandial and postabsorptive periods may have
Table 3. Changes in subjective appetite scores from baseline to 12 weeks
Variable Group Sample
size (n)
Mean difference
(95% CI) 6 weeks
Mean difference
(95% CI) 12 weeks
P-valuea
Time Treatment Time× treatment
Appetite Placebo 21 − 0.33 (−0.77 to 0.11) − 0.24 (−0.67 to 0.19) 0.002 0.01 0.18
Phosphorus 26 − 0.92 (−1.38 to − 0.47) − 0.73 (−1.24 to − 0.23)
Quantity of food to reach fullness Placebo 21 − 0.57 (−0.94 to − 0.20) − 0.33 (−0.77 to 0.11) o0.001 0.04 0.30
Phosphorus 26 − 0.85 (−1.24 to − 0.46) − 0.81 (−1.25 to − 0.37)
Hunger Placebo 21 − 0.62 (−1.09 to − 0.15) − 0.33 (−0.75 to 0.08) o0.001 0.31 0.53
Phosphorus 26 − 0.73 (−1.15 to − 0.31) − 0.73 (−1.12 to − 0.34)
Taste of food Placebo 21 0.00 (−0.20 to 0.20) − 0.05 (−0.32 to 0.22) 0.09 0.007 0.16
Phosphorus 26 − 0.31 (−0.56 to − 0.06) − 0.35 (−0.60 to − 0.09)
Number of main meals Placebo 21 0.14 (−0.08 to 0.36) 0.19 (0.01 to 0.37) 0.76 0.59 0.90
Phosphorus 26 0.08 (−0.47 to 0.62) 0.04 (−0.50 to 0.58)
Number of snacks Placebo 21 − 1.90 (−0.61 to 0.23) − 0.10 (−0.55 to 0.36) 0.04 0.01 0.21
Phosphorus 26 − 0.81 (−1.33 to − 0.28) − 0.81 (−1.39 to − 0.23)
Abbreviation: CI, conﬁdence interval. aP-values for repeated measures analysis of variance (ANOVA).
Table 2. Changes in anthropometric and biochemical characteristics from baseline to 12 weeks
Indicator Placebo group Phosphorus group P-valuea, placebo vs
phosphorus
Sample
sizeb
Mean difference
(95% CI)
P-valuec Sample
sizeb
Mean difference
(95% CI)
P-valuec
Anthropometric measurements
Weight, kg 21 1.13 (0.19 to 2.06) 0.02 26 − 0.65 (−1.69 to 0.40) 0.22 0.01
BMId 21 0.42 (0.05 to 0.78) 0.03 26 − 0.24 (−0.59 to 0.12) 0.19 0.01
Waist circumference, cme 21 0.38 (−0.44 to 1.20) 0.35 26 − 3.62 (−4.90 to − 2.33) o0.001 o0.001
Biochemical characteristics
Serum phosphorus, mg dl− 1 20 0.163 (0.034 to 0.292) 0.82 26 − 0.111 (−0.299 to 0.077) 0.78 0.017
Total cholesterol, mg dl− 1 20 − 1.00 (−12.83 to 10.83) 0.86 25 0.92 (−11.45 to 13.29) 0.88 0.82
LDL-C, mg dl− 1 20 2.37 (−10.10 to 14.84) 0.70 25 1.43 (−8.71 to 11.58) 0.77 0.90
HDL-C, mg dl− 1 20 0.95 (−1.57 to 3.47) 0.44 25 − 0.04 (−3.59 to 3.51) 0.98 0.64
Triglycerides, mg dl− 1 20 − 20.30 (−41.70 to 1.20) 0.06 25 − 2.92 (−21.66 to 15.82) 0.75 0.21
Glucose, mg dl− 1 20 − 1.35 (−5.97 to 3.27) 0.55 25 0.64 (−6.98 to 8.26) 0.86 0.65
Insulin, mg dl− 1 20 − 2.61 (−6.52 to 1.29) 0.18 25 2.01 (−0.56 to 4.58) 0.12 0.05
HOMA-IR 20 − 0.77 (−1.89 to 0.35) 0.17 25 0.79 (−0.26 to 1.83) 0.13 0.04
CRP, mg dl− 1 20 1.25 (−0.65 to 3.15) 0.19 25 0.18 (−1.68 to 2.04) 0.84 0.41
Abbreviations: BMI, body mass index; CI, conﬁdence interval; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic
model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol. SI conversion factor: to convert serum phosphorus to mmol l− 1, multiply by
0.323; cholesterol, LDL-C and HDL-C to mmol l− 1, multiply by 0.0259; triglycerides to mmol l− 1, multiply by 0.0113; glucose to mmol l− 1, multiply by 0.0555.
aP-value for intergroup comparisons using two-sample t-test. bBased on analysis of patients for whom data were available. cP-values for pairwise intragroup
comparisons obtained using paired t-test. dCalculated as weight in kg divided by height in m squared. eMeasured at the midpoint between the lower rib and
iliac crest.
Phosphorus supplement and obesity
JJ Ayoub et al
4
Nutrition & Diabetes (2015) 1 – 6
contributed to the observed reduction in appetite and number of
snacks and these may have been translated by subjects into taste
changes. Conversely, the similarity in the scores of hunger (that is,
physiological controlled by depletion of energy stores) and the
number of main meals between the phosphorus and placebo
groups may be explained by a limited availability of hepatic ATP
substrates beyond postprandial and postabsorptive periods, and
thus an inability to impact the initiation of the next main meal. In
brief, the impact of phosphorus supplement on energy intake
seems to be related to its capacity to reduce the size of main
meals (low appetite and high fullness) as well as intake between
meals (number of snacks).
Furthermore, the favorable differences in body weight and
waist circumference in the phosphorus group may have been
partially related to an effect of phosphorus on energy metabolism.
The addition of phosphorus to orange juice was reported to
increase postprandial thermogenesis among obese but not lean
subjects.34,35 In addition, phosphorus supplementation in a weight
reducing program was found to increase resting metabolic rate of
obese subjects.36,37 The pronounced reduction in waist circum-
ference in the face of the modest reduction in body weight may
have been attributed to changes in body composition. Weight
gain under phosphorus-deﬁcient diet was reported to be largely
attributed to an increase in adipose tissue, whereas nitrogen
retention was impaired,38 and this seems to mimic that of low-
protein (low-phosphorus) diet.23 Changes in body fat were
reported to be related to energy intake, whereas changes in lean
body mass were related to the intake of protein,23 known to be
high in phosphorus and this raises a question of whether the
effect of protein on weight gain is linked to its content of
phosphorus. It is not clear whether phosphorus supplementation
favored lean body mass retention that ultimately masked the
effect on changes in body weight because of its capacity to retain
water. In any case, the observed reduction in waist circumference
was similar to that reported in subjects under low-fat diets,22 and
is believed to be of clinical signiﬁcance as it is an indicator of
abdominal obesity (visceral fat) that is known to be a risk factor of
type 2 diabetes and cardiovascular disease.39,40
Many concerns were raised on the relation between phos-
phorus status and cardiovascular disease and mortality,41,42
although the nature of the relation with phosphorus intake is far
from clear and requires further scrutiny,43 especially as fasting
serum phosphorus does not reﬂect intake30,44 as conﬁrmed by our
results. The fact that fasting but not nonfasting (that reﬂects intake
rather than clearance) serum phosphorus levels were associated
with increased mortality45 and fasting serum phosphorus level but
not dietary intake were associated with coronary artery
calciﬁcation46 may imply that factors behind or associated with
elevated fasting serum phosphorus rather than phosphorus intake
may have attributed to these detrimental effects. The recent
reported weak association between dietary phosphorus intake
and all-cause mortality44 was questioned as varied dietary habits
or proﬁles were seen among the different dietary phosphorus
intake quartiles. Moreover, such association may have been
cofounded by the source of phosphorus in the diet, especially
as dietary heme iron intake (derived from animal source that is
also high in phosphorus) was shown to increase the risk of
cardiovascular disease.47 It is believed that the need of
phosphorus especially for carbohydrate metabolism may have
been compromised by modernization (reﬁnement and so on),
particularly in staple carbohydrate-rich foods (rice, wheat and so
on). The impact of such a compromise is expected to depend on
the contribution of staple food to total energy intake and may
partially be behind the drastic increase in obesity in developing
countries, in particular as carbohydrate contribution to total
energy intake is inversely related to income.48
The weaknesses of the study include: the lack of biomarker for
phosphorus intake, the use of the subjective self-reported visual
analog scale (VAS) for the determination of appetite scores and
the lack of analyses for body composition and energy expenditure.
The strength of our study was that a rigorous system of training
and certiﬁcation of study personnel was developed and imple-
mented for collecting all data. In addition, our study is pragmatic,
randomized, double blinded and placebo controlled that required
the use of tablets without requesting behavioral or dietary
changes to avoid the problem of adherence.
CONCLUSION
In summary, this 12-week randomized, placebo-controlled trial
showed that phosphorus supplementation (375 mg per main
meal) halted weight gain and BMI while signiﬁcantly decreasing
waist circumference. This may have been related to favorable
changes in body composition. At the same time, these changes
were associated with early satiation, whereas satiety (number of
main meals) and hunger were not altered. Our ﬁndings support a
promising role of the mineral phosphorus in preventing obesity,
especially abdominal adiposity. Therefore, after extensive investi-
gations, phosphorus utilization could be considered for the future
development of weight maintenance or reduction supplements or
implementation of ﬂour fortiﬁcation. Additional research is
warranted to examine the exact mechanisms of actions and
longer-term effects of phosphorus.
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